Multiple Nutritional Deficiencies Causing Dementia of the Alzheimer Type
NCT ID: NCT01479855
Last Updated: 2013-11-27
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
180 participants
OBSERVATIONAL
2012-01-31
2013-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
A second aim is to explore the association between vitamin and nutrient reductions, if any, and cognitive function as well as vascular score and possible changes in the MRI.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
In an earlier pilot study conducted on AD patients in a moderate stage, there were significant decrease in the concentrations of the vitamins thiamine, pyridoxal-5 phosphate, ascorbic acid retinol, cobalamin, and increased homocystein, compared with the control group of healthy elderly people. Logistic regression analysis showed that 5 models using different combinations of vitamins and spinal protein, all completely separating patients with dementia from healthy controls.
The current study is a replication of the above mentioned study, and will include up to 120 AD patients with mild cognitive impairment (MCI) or mild dementia (MMSE above 24/30) and up to 60 healthy elderly controls. Measurement of vitamines and nutrients in blood and spinal fluid is the central element of the study. The specimens will therefore be obtained from patients and controls who have abstained from supplements the last four weeks.
Outcome measures will include biochemical analysis of nutrients, expressions of peroxidation, expressions of DNA damage, proteomics and metabolomics of spinal fluid, blood and urine, microarray analysis of different nutritional deficiency subgroups, together with the routine diagnostics investigations undertaken at the memory clinic, and a nutritional assessment.
The patients and the healthy controls will only receive information about results of examinations that are part of the routine investigation at the memory clinic, this according to the Norwegian Biotechnology Law and the permission from the National Committees for Research Ethics in Norway.
In addition to the vitamins listed as primary outcomes, the following measurements will be carried through:
1. Isoprostane measurements: The findings of F2-α-isoprostane-increase in cerebrospinal fluid close to the diseased organ, and not in the plasma, makes it important to confirm these findings. Isoprostane measurement in CNS might become an important parameter in prospective treatment studies where the actual treatment at least should normalize the pathological finding.
2. 8 hydroxy-2-deoxy guanosine increase in cerebrospinal fluid or urine, reveals DNA-damage suggesting further mechanisms for the AD development.
3. Spinal fluid: Nutrients in spinal fluid, expressions of increased peroxidation like F2-α-isoprostane, tau proteins and possibly with LC/MS methodology metabolic pattern (metabolomics) and different proteins (proteomics).
* Proteomics; determination of protein profiles. The emerging technology of mass spectrometry (MS)-based quantitative proteomics provides a powerful tool to systematically and quantitatively assess quantitative differences in protein profiles. Discovery based proteomics compares the proteome of a diseased sample versus normal at a global scale, and has been widely applied to study various human diseases with the goal of identifying biomarkers and/or reveal the pathogenesis of diseases. In this study, protein samples from control and diseased will be labeled with different stable isotopes, digested to peptides and analyzed by LCMS. Quantitative differences of the proteins from these groups will be performed by state-of-the-art hybrid mass spectrometer, LTQ XL-Orbitrap. The Orbitrap instrument has extremely high resolving power, mass accuracy and sensitivity.
* Metabonomics: Metabonomics aims at measuring and mathematically modeling changes in the metabolite concentrations found in biological fluids and tissues. Nuclear magnetic resonance (NMR) spectroscopy allows the detection and quantification of compounds in large mixtures, such as the products of metabolism in biological fluids and tissues. There are hundreds of such metabolites to be found in cerebrospinal fluid, plasma, serum and urine. NMR spectroscopy offers the advantage of measuring their concentrations with micromolar sensitivity while conveniently requiring only little sample preparation. In recent studies involving large sets of spectra, the variation of results was shown to be as small as 2 % reflecting a high degree of reproducibility. By identifying patterns in the metabolic fingerprint of the organism, one can study the effects of diet, drugs and disease using multivariate statistics such as principal component analysis and partial least squares attempts to interpret NMR spectra.
4. Genetic analyses: m-RNA measurement with SNP-profiles for
* DNA repair.
* Active components in processing av APP and Abeta.
* Will include if possible, sequencing of genome and/or GWAS.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Patients
Patients referred to a memory clinic due to memory problems and their healthy spouse
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Depression score below 9 both on MADRS and Cornell.
Exclusion Criteria
* Lewy Body Dementia or Frontal Lobe Dementia.
* Dementia due to a known brain vascular disturbance, hemorrhage or thrombosis.
* Patients who had not stopped their intake of vitamins and food additives the last four weeks.
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
South Eastern Area Health Service
OTHER
Oslo University Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Ingun D Ulstein, MD PhD
Role: PRINCIPAL_INVESTIGATOR
Oslo University Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
OsloUH, Ullevål
Oslo, , Norway
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
References
Explore related publications, articles, or registry entries linked to this study.
Glaso M, Nordbo G, Diep L, Bohmer T. Reduced concentrations of several vitamins in normal weight patients with late-onset dementia of the Alzheimer type without vascular disease. J Nutr Health Aging. 2004;8(5):407-13.
Aebersold R, Mann M. Mass spectrometry-based proteomics. Nature. 2003 Mar 13;422(6928):198-207. doi: 10.1038/nature01511.
Nicholson JK, Lindon JC. Systems biology: Metabonomics. Nature. 2008 Oct 23;455(7216):1054-6. doi: 10.1038/4551054a. No abstract available.
Mercier P, Lewis MJ, Chang D, Baker D, Wishart DS. Towards automatic metabolomic profiling of high-resolution one-dimensional proton NMR spectra. J Biomol NMR. 2011 Apr;49(3-4):307-23. doi: 10.1007/s10858-011-9480-x. Epub 2011 Mar 1.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Other Identifier
Identifier Type: OTHER
Identifier Source: secondary_id
2011/698 (REK)
Identifier Type: -
Identifier Source: org_study_id